GW-TT3

About Gateway Biotechnology

Gateway Biotechnology is a private, clinical-stage company pioneering novel treatments for hearing loss and tinnitus. Its lead program, GW-TT2, is an intranasal formulation of a repurposed drug targeting recent-onset tinnitus and is advancing under the FDA's 505(b)(2) regulatory pathway to reduce cost and risk. The company's scientific foundation is built on proprietary behavioral detection models and the expertise of its academic co-founders from Washington University in St. Louis and the University of Pittsburgh.

Therapeutic Areas